Search Results - "AVERKOV, O. V."

Early discontinuation of dual antiplatelet therapy via acetylsalicylic acid cessation in patients with acute coronary syndrome undergoing percutaneous coronary interventions to reduce the bleeding risk by Averkov, O. V.

“…Early percutaneous coronary intervention (PCI) and long-term aggressive antithrombotic treatment based on dual antiplatelet therapy (DAPT) are the most…”
Get full text

The Role of Rivaroxaban in the Treatment of Patients with Stable Coronary Artery Disease by Averkov, O. V.

“…An analytical article discusses the design and results of the recent COMPASS study. Particular attention is paid to the details of comparison of the efficacy…”
Get full text

Gastrointestinal Bleeding: a Cardiologist's Point of View by Averkov, O. V., Mishchenko, L. N.

“…Oral anticoagulant therapy is widely used in different patients for the prevention and treatment of thromboembolic events: in atrial fibrillation, deep vein…”
Get full text

New SARS-CoV-2 Omicron variant — clinical picture, treatment, prevention (literature review) by Vechorko, V. I., Averkov, O. V., Zimin, A. A.

“…Despite the decrease in the incidence rate, today the problem of a coronavirus disease 2019 (COVID-19) remains relevant on a global scale. Among the Severe…”
Get full text

Pulmonary Sequelae of COVID-19 in Patients With Lung Damage Over 75% (CT-4) by Komissarova, K. V., Godzenko, A. V., Doroshenko, D. A., Gordeev, I. G., Averkov, O. V., Vechorko, V. I.

“…Introduction: A number of studies uses severity of lung damage as a predictor of lung changes in the long-term period. Objective: To evaluate computed…”
Get full text

ANTI-THROMBOCYTIC DRUGS FOR ACUTE CORONARY SYNDROME: DIRECT COMPARISON OF HEMORRHAGIC SAFETY THROMBOCYTE P2Y12-RECEPTOR BLOCKERS TICAGRELOR AND CLOPIDROGEL (BASED ON PLATO STUDY RESULTS by O. V. AVERKOV

“…Double anti-platelet therapy (DAPT) comprising a combination of acetylsalicylic acid and one of the thrombocyte P2Y12-receptor blockers is considered an…”
Get full text

NEWS2, 4C Mortality Score, COVID-GRAM, Sequential Organ Failure Assessment Quick scales as outcomes assessment tools for severe COVID-19 (pilot retrospective cohort study) by Vechorko, V. I., Averkov, O. V., Grishin, D. V., Zimin, A. A.

“…Aim . To study the predictive ability of the NEWS2, 4C Mortality Score, COVID-GRAM and qSOFA scales in predicting clinical outcomes in patients with severe…”
Get full text

Selection of P2Y12 antagonist in patients with myocardial infarction who received thrombolytic therapy. Results of annual follow-up of TREAT study patients by Averkov, O. V., Vechorko, V. I.

“…Dual antiplatelet therapy serves to improve the clinical results of thrombolytic therapy after STEMI, until recently consisted of acetylsalicylic acid and…”
Get full text

APPLICATION OF RIVAROXABAN IN ACUTE CORONARY SYNDROME: EVIDENCE AND CURRENT GUIDELINES by Averkov, O. V.

“…The analytical article focuses on the data concerning duration of anticoagulation treatment in acute coronary syndrome patients. The information provided on…”
Get full text

The Effect of Carriage of CYP3A53 and CYP3A422 Polymorphic Variants on the Safety of Remdesivir Therapy in Patients with COVID-19 by TEMIRBULATOV, I. I., KRYUKOV, A. V., MIRZAEV, K. B., DENISENKO, N. P., ABDULLAEV, S. P., ZHIRYAKOVA, A. S., SHEVCHUK, Y. V., VECHORKO, V. I., AVERKOV, O. V., SYCHEV, D. A.

“…The aim of the study was to assess the association of polymorphic variants CYP3A5*3 6986 A>G rs776746 and CYP3A4*22 rs35599367 C>T with the safety parameters…”
Get full text

Ticagrelor and thrombolysis in myocardial infarction: what does the TREAT study change? by Averkov, O. V., Vechorko, V. I.

“…Primary percutaneous intervention (PCI) is a preferable reperfusion method in patients with STEMI. If on-time PCI is not possible, pharmacoinvasive approach is…”
Get full text

Model for predicting risk of developing drug-induced liver injury during remdesivir therapy: observational prospective open case-control study by Shevchuk, Yu. V., Kryukov, A. V., Temirbulatov, I. I., Sychev, I. V., Mirzaev, K. B., Denisenko, N. P., Abdullaev, Sh. P., Tuchkova, S. N., Vechorko, V. I., Averkov, O. V., Sychev, D. A.

“…Remdesivir is a drug widely used for the etiotropic treatment of COVID-19. According to a number of studies, the incidence of adverse reactions during…”
Get full text

Safety of Pharmacotherapy in COVID-19 Patients: A Literature Review by Kryukov, A. V., Zhiryakova, A. S., Shevchuk, Yu. V., Matveev, A. V., Vechorko, V. I., Averkov, O. V., Glagolev, S. V., Temirbulatov, I. I., Mirzaev, K. B., Denisenko, N. P., Abdullaev, Sh. P., Sychev, D. A.

“…The safety of COVID-19 pharmacotherapy is a relevant issue, first of all, because of the current lack of experience with using particular medicinal products…”
Get full text

Therapeutic potential of apixaban at different stages of management of patients with pulmonary thromboembolism by Averkov, O. V., Vechorko, V. I., Shapsigova, O. A.

“…The article discusses the issues of anticoagulant therapy in pulmonary thromboembolism. It clearly highlights the main advantages and the preferred use of…”
Get full text

MODERN APPROACHES TO ANTICOAGULANT THERAPY OF PULMONARY EMBOLISM: FOCUS ON RIVAROXABAN by O. V. Averkov, V. I. Vechorko

“…The analytical article provides a modern state of the anticoagulant therapy in pulmonary thromboembolism. Major advantages and preferential use of direct…”
Get full text

COVID-19 infection after recent heart transplantation: a case report by Vechorko, V. I., Gordeev, I. G., Gubareva, E. V., Ryndyaeva, E. V., Averkov, O. V.

“…History of heart transplantation in combination with immunosuppressive therapy and acute viral respiratory infection overlay makes the patient difficult to…”
Get full text

Recommendations of the Society of Specialists in Urgent Cardiology Diagnosis and Treatment of Patients With Non-ST-Segment Elevation Acute Coronary Syndrome. Part 1 by YAvelov, S I, Ruda, Y M, Averkov, V O, Panchenko, P E

Get more information

Clopidogrel in the treatment of patients with ST-elevation acute myocardial infarction: state-of-art in 2013 by Averkov, O. V.

“…This analytical paper presents the modern evidence on the dual antiplatelet therapy in ST-elevation myocardial infarction. A possible replacement of one dual…”
Get full text

ACETYLSALICYLIC ACID AND PREVENTION OF FATAL OUTCOMES IN CARDIOVASCULAR DISEASE: SELECTING MEDICATION FORM AND DOSE by O. V. Averkov

“…This analytic paper presents the evidence on the potential of acetylsalicylic acid (ASA) for the mortality reduction in patients with cardiovascular disease…”
Get full text

Place of Prasugrel, P2Y12 receptor antagonist, in an early invasive treatment of patients with acute coronary syndrome (according to the results of multicenter randomized controlled trial ISAR-REACT 5) by Tereshchenko, S. N., Glezer, M. G., Abugov, S. A., Averkov, O. V., Antipov, S. I., Galyavich, A. S., Gilyarov, M. Yu, Duplyakov, D. V., Efremushkina, A. A., Zateyshchikov, D. A., Ivanenko, V. V., Kosmacheva, E. D., Krestyaninov, O. V., Lopatin, Yu. M., Panchenko, E. P., Ryabov, V. V., Samokhvalov, E. V., Staroverov, I. I., Ustyugov, S. A., Khripun, A. V., Shalaev, S. V., Shakhnovich, R. M., Yavelov, I. S., Yakovlev, A. N., Yakushin, S. S.

“…The conclusion of the Expert Council reports an agreement on the place of the P2Y12 receptor blocker prasugrel in the early invasive treatment of patients with…”
Get full text